Invention Grant
US08790647B2 Treatment of vasculoproliferative conditions with Lrg1 anatgonists
有权
用Lrg1阴茎病人治疗血管增生症状
- Patent Title: Treatment of vasculoproliferative conditions with Lrg1 anatgonists
- Patent Title (中): 用Lrg1阴茎病人治疗血管增生症状
-
Application No.: US13393531Application Date: 2010-09-06
-
Publication No.: US08790647B2Publication Date: 2014-07-29
- Inventor: John Greenwood , Stephen Moss , Xiaomeng Wang
- Applicant: John Greenwood , Stephen Moss , Xiaomeng Wang
- Applicant Address: GB Great Britain
- Assignee: UCL Business PLC
- Current Assignee: UCL Business PLC
- Current Assignee Address: GB Great Britain
- Agency: Morrison & Foerster LLP
- Priority: GB0915515.1 20090904
- International Application: PCT/GB2010/001681 WO 20100906
- International Announcement: WO2011/027129 WO 20110310
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
This invention relates to the field of molecular physiology. Specifically, this invention relates to treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.
Public/Granted literature
- US20120231002A1 TREATMENT OF VASCULOPROLIFERATIVE CONDITIONS Public/Granted day:2012-09-13
Information query
